Oscient to cut sales and marketing forces by 180

Share this article:
Waltham, MA-based Oscient Pharmaceuticals announced a restructuring that will result in 180 layoffs, including its 150-person sales force and approximately 30 other sales and marketing positions, the company said in a release. The layoffs with begin next month.

The cuts follow the company's decision – based on the conservation of financial resources – to discontinue sales force promotion on two products: Antara (fenofibrate), a cardiovascular drug, and Factive (gemifloxacin mesylate), an antibiotic. The products will continue to be available to physicians and patients.

The company reported a net loss of $11.5 million during the fourth quarter of 2008, up from a net loss of $14.7 million in Q4 2007, according to an annual report. Sales revenue for Antara was up during the same period, reaching $21.2 million during the fourth quarter, from $19.3 million during Q4 2007. Factive, however, decreased from $5.9 million during Q4 of 2007 to $5.1 million during Q4 2008, according to the report.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...